Evidence map›Paper›PMID 36631838›Full record

ArticleEuropean journal of medical research2023

Searching for a prognostic index in lupus nephritis.

E Rodríguez-Almaraz, E Gutiérrez-Solís, E Rabadán, P Rodríguez, M Alonso, L Carmona, M J García de Yébenes, E Morales, M Galindo-Izquierdo

Open access · goldAbstract read
In one paragraph

Article in European journal of medical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Lupus Nephritis Risk Factors and Biomarkers: An Update.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

E Rodríguez-AlmarazDepartment of Rheumatology, University Hospital "12 de Octubre", Avda. Córdoba Km 5.400, 28041, Madrid, Spain. mralmaraz@salud.madrid.org.ORCID http://orcid.org/0000-0003-0839-5644
E Gutiérrez-SolísDepartment of Nephrology, University Hospital "12 de Octubre", Madrid, Spain.
E RabadánDepartment of Rheumatology, University Hospital "12 de Octubre", Avda. Córdoba Km 5.400, 28041, Madrid, Spain.
P RodríguezDepartment of Nephrology, University Hospital "12 de Octubre", Madrid, Spain.
M AlonsoDepartment of Pathology, University Hospital "12 de Octubre", Madrid, Spain.
L CarmonaInstituto de Salud Musculoesquelética (Inmusc), Madrid, Spain.
M J García de YébenesInstituto de Salud Musculoesquelética (Inmusc), Madrid, Spain.
E Morales *Department of Nephrology, University Hospital "12 de Octubre", Madrid, Spain.
M Galindo-Izquierdo *Department of Rheumatology, University Hospital "12 de Octubre", Avda. Córdoba Km 5.400, 28041, Madrid, Spain.
Research Institute Hospital 12 de Octubre · ESInstituto de Salud Musculoesquelética · ESUniversidad Complutense de Madrid · ES

Funding

Fundación Madrileña de Nefrología 2017/0122Sociedad de Reumatología de la Comunidad de Madrid 2017/0030
6 · The paper itself

Abstract

backgroundCurrently we do not have an ideal biomarker in lupus nephritis (LN) that should help us to identify those patients with SLE at risk of developing LN or to determine those patients at risk of renal progression. We aimed to evaluate the development of a prognostic index for LN, through the evaluation of clinical, analytical and histological factors used in a cohort of lupus. We have proposed to determine which factors, 6 months after the diagnosis of LN, could help us to define which patients will have a worse evolution of the disease and may be, more aggressive treatment and closer follow-up.

methodsA retrospective study to identify prognostic factors was carried out. We have included patients over 18 years of age with a clinical diagnosis of systemic lupus erythematosus (SLE) and kidney involvement confirmed by biopsy, who are followed up in our centre during the last 20 years. A multi-step statistical approach will be used in order to obtain a limited set of parameters, optimally selected and weighted, that show a satisfactory ability to discriminate between patients with different levels of prognosis.

resultsWe analysed 92 patients with LN, although only 73 have been able to be classified according to whether or not they have presented poor renal evolution. The age of onset (44 vs. 32; p = 0.024), the value of serum creatinine (1.41 vs. 1.04; p = 0.041), greater frequency of thrombocytopenia (30 vs. 7%; p = 0.038), higher score in the renal chronicity index (2.47 vs. 1.04; p = 0.015), proliferative histological type (100%) and higher frequency of interstitial fibrosis (67 vs. 32%; p = 0.017) and tubular atrophy (67 vs. 32%; p = 0.018) was observed between two groups. The multivariate analysis allowed us to select the best predictive model for poor outcome at 6 months based on different adjustment and discrimination parameters.

conclusionWe have developed a prognostic index of poor renal evolution in patients with LN that combines demographic, clinical, analytical and histopathological factors, easy to use in routine clinical practice and that could be an effective tool in the early detection and management.

Indexed as

Lupus Erythematosus, SystemicLupus NephritisAdolescentAdultHumansKidneyPrognosisRetrospective StudiesLupus nephritisPoor renal evolutionPrognostic index

Identifiers

PMID36631838
PMCPMC9832788
OpenAlexW4315650161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.